July 24, 2026

The Manager (Listing),
National Stock Exchange of India Limited,
Exchange Plaza, Plot No. C/1, G Block,
Bandra-Kurla Complex, Bandra (East),
Mumbai - 400 051

Symbol: AVIENCE

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") – Investors / Earnings Presentation

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI Listing Regulations, please find attached herewith Investors/ Earnings Presentation in connection with Earnings Conference Call for investors scheduled as on July 24, 2026 at 04.00 P.M. (IST) to discuss the Audited Standalone and Consolidated Financial Results of the Company for the half year and financial year ended March 31, 2026.

The above information is also available on the website of the Company i.e., https://avienbio.com/

Kindly take the same on records.

Thanking you,

Yours faithfully.

For **AVIENCE BIOMEDICALS LIMITED**
(Formerly known as Avience Biomedicals Private Limited)

DHARAM DEO CHOUDHARY

Digitally signed by DHARAM DEO CHOUDHARY
DN: c=IN, postalCode=201301, st=UTTAR PRADESH, street=G -1 0 SECTOR -11 NOIDA UTTAR PRADESH, l=GAUTAMBUDDHA NAGAR, o=AVIENCE BIOMEDICALS LIMITED, ou=AVIENCE BIOMEDICALS LIMITED, serialNumber=b649e0a72a92d75074624282a9dfab7161f97c934aa1e2d82198438e9dc7bada, pseudonym=d88278966448f6b5adef28cdf494c5d7, 2.5.4.20=e6c5788637fd63c35e679a3b25c1fd831a404d77f6391e98372aebc9ec39d554, email=DDCHOUDHARY@AVIENBIO.COM, cn=DHARAM DEO CHOUDHARY
Date: 2026.07.24 12:36:20 +05'30'

DHARAM DEO CHOUDHARY
Managing Director
DIN- 02804625
Address: Flat No 48, Suryodaya Apartment,
Pocket 8, Sec-12, Dwarka, Dist: South West Delhi,
Delhi – 110078

Encl: As above

AVIENbio®
Complete Healthcare Solution

AVIENCE BIOMEDICALS LIMITED

INVESTOR PRESENTATION

DISCLAIMER

This presentation has been prepared by Avience Biomedicals Limited solely for informational purposes. The information contained herein is intended to provide a general overview of the Company, its business operations, products, services, industry and growth strategy. It does not constitute an offer, invitation, recommendation or solicitation to purchase or subscribe for any securities or other financial instruments, nor should it be construed as investment, legal, accounting, regulatory or tax advice. Certain information, illustrations, graphics, photographs and visuals contained in this presentation are intended for illustrative purposes only and may not represent the Company's actual products, facilities, operations or future performance. While reasonable care has been taken in preparing this presentation and the information is believed to be accurate as of the date of publication, Avience Biomedicals Limited makes no representation or warranty, express or implied, regarding the accuracy, completeness or reliability of the information contained herein. The Company, its directors, officers, employees and advisors shall not be liable for any direct or indirect loss arising from the use of, or reliance upon, this presentation. This presentation may contain forward-looking statements relating to the Company's business prospects, expansion plans, manufacturing capabilities, product portfolio, market opportunities, financial performance and growth strategy. Such statements are based on current expectations and assumptions and are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied. The Company undertakes no obligation to update or revise any forward-looking statements to reflect future events or developments. Any industry data, market information or third-party reports referred to in this presentation have been obtained from publicly available sources believed to be reliable. However, such information has not been independently verified by the Company, and no representation is made regarding its accuracy or completeness. Recipients are advised to conduct their own independent evaluation of the Company and seek appropriate professional advice before making any business, financial or investment decisions based on the information contained in this presentation.

COMPANY SNAPSHOT

Avience Biomedicals Limited

is an integrated diagnostics and medical devices company engaged in manufacturing, distribution, and marketing of IVD products, reagents, analyzers, and medical consumables across India.

ESTABLISHED
2019
Year of Incorporation

MANUFACTURING FACILITY
NOIDA
Uttar Pradesh

PRODUCT PORTFOLIO
IVD Kits, Reagents, Analyzers & Consumables

CDSCO APPROVALS
88
Approved Products

PRODUCT PIPELINE
200+
Applications Under Process

BUSINESS MODEL
Manufacturing + Distribution

PRESENCE
PAN INDIA
Network

CUSTOMERS
Government & Private Healthcare Institutions

QUALITY CERTIFICATIONS
ISO 13485:2016,
ISO 9001:2015

MANUFACTURING FACILITY
State-of-the-art facility in Noida, Uttar Pradesh

EXPANSION
Fully Automated Medical Device Park Facility in UP

STRATEGIC PARTNERSHIP
Authorized Distributor for Mindray in India

BUSINESS MODEL

01 MANUFACTURING OF

- IVD Kits
- Reagents
- Consumables
- Diagnostic Products

02 DISTRIBUTION & STRATEGIC PARTNERSHIPS

Pan India distribution network and strategic collaborations

03 PLACEMENT OF DIAGNOSTIC INSTRUMENTS / ANALYZERS

Installed at customer locations

04 RECURRING CONSUMABLES & REAGENT REVENUE

Repeat purchases driving sustainable revenue

05 LONG-TERM INSTITUTIONAL CUSTOMER RELATIONSHIPS

Strong trust, retention and long-term growth

SCALABLE RECURRING REVENUE MODEL

- Consumables-driven repeat business
- Strong customer retention
- High operating leverage potential
- Integrated manufacturing + distribution ecosystem

SERVING A DIVERSE CUSTOMER BASE

- GOVERNMENT HOSPITALS
- PRIVATE LABS
- DIAGNOSTIC CENTERS
- HEALTHCARE INSTITUTIONS

MEET OUR TEAM

Mr. Dharam Deo Choudhary

Promoter & Managing Director

- Educational background includes a Bachelor of Commerce and member of ICMAI.
- 30 years of experience across accounts, finance, and business management with deep strategic and financial expertise.
- 15-year tenure as Director of M/s DR Meditech Surgical and Diagnostics India Pvt. Ltd., with deep understanding of the IVD business.
- Committed to operational efficiency, financial sustainability, and strategic decision-making to drive the company's growth.

MEET OUR TEAM

Mrs. Deepa Choudhary
Promoter & Executive Director

- Aged 37 years, holds a Bachelor of Arts degree from Chhatrapati Shahu ji Maharaj University, Kanpur.
- 5 years of experience in formulating and implementing strategic business development.
- Expert in market analysis, relationship building, and strategic planning.
- Identifies new opportunities and ensures consistent success.

CA. Om Prakash Pal
Independent Director

- Practicing Chartered Accountant.
- 16+ years of experience in Audit, Direct Taxation, Finance & Consultancy.
- Strong expertise in financial strategy, regulatory compliance & tax planning.
- Advises the board to improve financial discipline and transparency.

Mr. Janardan Pal
Promoter & Non-Executive Director

- Aged 43 years, holds a Bachelor of Commerce degree from the University of Delhi (2005).
- 13 years of experience in strategic planning and guiding operational initiatives.
- Serving the company since its incorporation and plays a key role in shaping strategic direction.

Mr. Pankaj Sharma
Independent Director

- B.Tech (Chemical Engineering) from IIT Delhi and M.S. (Consultancy Management) from BITS Pilani.
- 30+ years of experience in business management, engineering, project execution, and entrepreneurship.
- Worked with reputed organizations such as C2C Technosoft, UOP India Pvt. Ltd., and Foster Wheeler Energy Ltd.
- Contributes strong strategic thinking, technical expertise, and governance oversight.

Mr. Ram Nagina Choudhary
Promoter & Whole Time Director

- Seasoned professional with over 22 years of experience in daily operations, managing logistics, and execution of supply chain.
- Serving as Director of Avience Biomedicals Limited, bringing expertise in surgical and diagnostic distribution.
- 15-year tenure as Director of M/s DR Meditech Surgical and Diagnostics India Pvt. Ltd.
- Strong background in supply chain management, operations, customer care, procurement, and business administration.

PRODUCT ECOSYSTEM

IVD KITS

- Rapid Test Kits
- Diagnostic Test Kits
- Screening Products

REAGENTS

- Biochemistry Reagents
- Hematology Reagents
- Diagnostic Solutions

Integrated Diagnostics & Medical Devices Platform

DIAGNOSTIC INSTRUMENTS

- Analyzers
- Electrolyte Systems
- Automated Diagnostic Equipment

MEDICAL CONSUMABLES

- Sample Collection Products
- Tubes & Accessories
- Lab Consumables

MOLECULAR DIAGNOSTICS

- PCR Related Products
- Advanced Diagnostic
- Solutions

HEALTHCARE SOLUTIONS

- Institutional Supply
- Government Healthcare Support

WIDE RANGE OF QUALITY PRODUCTS | INTEGRATED MANUFACTURING | STRONG R&D & INNOVATION FOCUS | HIGH QUALITY & REGULATORY COMPLIANCE | PAN INDIA PRESENCE ACROSS SEGMENTS

JOURNEY OF GROWTH

AVIENbio®
Complete Healthcare Solution

2019
Incorporation of Avience Biomedicals

- Incorporated on 23 December 2019

2020
Expansion of Product Portfolio

- IVD Kits
- Reagents & Consumables
- Diagnostic Solutions

2022
Strengthening Manufacturing Capabilities

- Expansion of manufacturing operations
- Enhanced regulatory compliance framework

2024
Corporate Milestone

- Conversion into Public Limited Company
- Renamed as Avience Biomedicals Limited

2025
Product & Regulatory Expansion

- Growing CDSCO approved product portfolio
- Continued product registrations and applications

2026+
Next Phase of Growth

- Fully Automated Medical Device Park Facility
- Capacity expansion across product categories

BUILDING AN INTEGRATED DIAGNOSTICS, MEDICAL DEVICES & HEALTHCARE SOLUTIONS PLATFORM

- WIDE RANGE OF QUALITY PRODUCTS
- INTEGRATED MANUFACTURING
- STRONG R&D & INNOVATION FOCUS
- HIGH QUALITY & REGULATORY COMPLIANCE
- NATIONWIDE CUSTOMER REACH ACROSS INDIA

MANUFACTURED PRODUCTS – COMPLETE DIAGNOSTIC SOLUTIONS

AVIENbio®
Complete Healthcare Solution

RAPID TEST KITS

Avisure Pregnancy Card

Avisure Pregnancy Strip

MOLECULAR

Covid-19 Hid RTqPCR ASSAY

H1N1 Swine Flu

CULTURE MEDIA

Viral Transport Solution

BIOCHEMISTRY ANALYZER

Avience Biochemistry

OXYGEN CONCENTRATOR

JAY-5AW

JAY-10

ELECTROLYTE ANALYZER & REAGENTS

AV Lyte 80 Analyzer

AV Lyte 90 Analyzer

HAEMATOLOGY ANALYZER & REAGENTS

3 Part Auto Haematology Analyzer

LYSE

Blood Cell Diluent

Avienbio's manufactured products empower healthcare professionals with accurate diagnostics, efficient workflows and better patient outcomes.

MANUFACTURING & QUALITY CONTROL

AVIENbio®
Complete Healthcare Solution

MANUFACTURING FACILITY



MANUFACTURING PROCESS

MANUFACTURING PROCESS

ASSEMBLING PROCESS FOR RAPID TEST KITS

PACKAGING POUCHES FOR RAPID TEST KITS

ASSEMBLY OF BIOCHEMISTRY MACHINE

QUALITY TESTING MACHINE FOR RAPID TEST KITS



EXPANSION PLAN

Scaling Manufacturing Capabilities for the Next Phase of Growth

Location	Land Area	Manufacturing Focus	Facility Type	Target Commissioning
Plot No. 70, Sector 28, YEIDA Medical Device Park	2,100 Sq. Meters	Biochemistry Analyzer Manufacturing	Fully Automated Manufacturing Facility	Oct - 26

Avience is investing **₹30.18 crore** in a fully automated manufacturing facility at YEIDA Medical Device Park, with operations targeted by **Oct - 26**

₹ 30.18 cr

Total Project Investment

FUNDING MIX

IPO Proceeds	₹15.95 Cr.
SIDBI Funding	₹12.00 Cr.
Internal Accruals	₹2.23 Cr.

STRATEGIC OBJECTIVES

- Expand Manufacturing Infrastructure
- Increase Production Capacity
- Support Product Diversification
- Strengthen Presence in Medical Devices
- Enhance Service to Hospitals, Laboratories & Research Institutions
- Capture Growth Opportunities in India's Diagnostics Industry

EXPECTED BENEFITS

- Higher Manufacturing Scale
- Improved Operational Efficiency
- Dedicated Analyzer Manufacturing Capability
- Enhanced Domestic & Export Potential
- Strong Platform for Long-Term Growth

CDSCO MANUFACTURING LICENSE PROCESS

1. **DOCUMENT COLLECTION** — Collation of documents for obtaining test license
2. **APPLICATION SUBMISSION** — Submission of application for test license
3. **TEST LICENSE ISSUED** — Issue of test license by CDSCO
4. **PRODUCT MANUFACTURING** — Manufacturing of the product
5. **PRODUCT TESTING** — Product testing through accredited laboratories
6. **PRODUCT APPROVAL** — Approval of product
7. **MANUFACTURING LICENSE APPLICATION** — Submission of application for manufacturing license
8. **REGULATORY EVALUATION** — Evaluation based on manufacturing track record and market standing certificate
9. **MANUFACTURING LICENSE ISSUED** — Issue of manufacturing license by CDSCO

AVERAGE TIMELINE

9–12 MONTHS

REGULATORY AUTHORITY

CDSCO

KEY TAKEAWAY

Manufacturing license approval involves multiple regulatory, testing and compliance stages, creating significant entry barriers and strengthening the competitive position of approved manufacturers.

CDSCO LICENSED PRODUCT PORTFOLIO

88 CDSCO Manufacturing Licenses Across Multiple Diagnostic Categories

AVIENbio®
Complete Healthcare Solution

BIOCHEMISTRY PRODUCTS — 43 Licenses

- Biochemistry Analyzers
- Glucose, Urea, Creatinine & Cholesterol Reagents
- Liver Function & Protein Testing Reagents
- Electrolyte Analyzers
- Laboratory Consumables & Collection Tubes

RAPID DIAGNOSTIC TEST KITS — 24 Licenses

- Dengue NS1 & Combo Test
- Malaria Pf/Pv & Pf/Pan Test
- HIV 1/2 Antibody Test
- HBsAg Test
- HCV Antibody Test
- Typhoid Test
- Syphilis Test
- Pregnancy Test Kits
- H. Pylori, Leptospira, Scrub Typhus & Others

HEMATOLOGY PRODUCTS

- Probe Cleaner
- Blood Cell Diluent
- LYSE Reagents

MICROBIOLOGY PRODUCTS

- Viral Transport Medium (VTM)

LICENSING ADVANTAGE

- 88 CDSCO Manufacturing Licenses Already Obtained
- Covers Diagnostics, Reagents, Consumables & Medical Devices
- Applications Under Process For **200+** Additional Products
- Strong Regulatory Entry Barrier For New Competitors

KEY TAKEAWAY

“Broad CDSCO-approved product portfolio enables Avience to offer end-to-end diagnostic solutions while creating a strong regulatory moat in the Indian diagnostics market.”

88 CDSCO Licenses	**4** Categories Diagnostic Segments	**200+** Products Under Approval

CUSTOMER & DISTRIBUTION NETWORK

PAN INDIA DISTRIBUTION PRESENCE

EXPANDING REACH
ACROSS MULTIPLE STATES

STRONG DISTRIBUTION
& CHANNEL NETWORK

INSTITUTIONAL &
HEALTHCARE FOCUSED
ECOSYSTEM

EFFICIENT PRODUCT
SUPPLY & SERVICE
SUPPORT

OUR CUSTOMER SEGMENTS

GOVERNMENT HOSPITALS

PRIVATE HOSPITALS

DIAGNOSTIC LABORATORIES

HEALTHCARE INSTITUTIONS

RESEARCH CENTERS

DISTRIBUTION PARTNERS

Strong customer relationships and distribution capabilities support recurring business growth.

PAN INDIA REACH	**WIDE INSTITUTIONAL** RELATIONSHIPS	**REPEAT BUSINESS** DRIVEN MODEL	**STRONG SERVICE** SUPPORT NETWORK	**SCALABLE CUSTOMER** ECOSYSTEM

INDUSTRY OUTLOOK

India's Diagnostics Industry Positioned for Strong Long Term Growth

AVIENbio®
Complete Healthcare Solution

Indian diagnostics market – In vitro vs In vivo (INR B, FY20-30P)



Indian IVD market by techniques (INR B, FY20-30P)



Source: Lattice Analysis

MARKET SNAPSHOT

- Indian diagnostics market expected to reach **₹ 1,964 Billion by FY30P**
- IVD segment contributed **~57%** of total diagnostics market in FY25
- Industry projected to grow at **11%+ CAGR** through FY30

KEY GROWTH DRIVERS

- **Rising disease burden:** TB • Diabetes • Cancer • Cardiovascular Diseases
- Rapid adoption of **molecular diagnostics**
- **AI automation & digital reporting** driving efficiency and accuracy
- **Government initiatives** and diagnostics expansion (NHM, Free Diagnostics Services)
- Increasing **health insurance penetration** (25% → 51%) improving affordability
- Expansion of organised diagnostic chains into **Tier-2 / Tier-3 markets**

LEADING PLAYERS

Roche | Abbott | SIEMENS Healthineers | TRANSASIA No.1 Diagnostic Company in India | BECKMAN COULTER

India's diagnostics industry is expected to witness sustained double digit growth, driven by rising healthcare awareness, technological advancements and expanding access to diagnostic services.

COMPETITIVE STRENGTHS

1

INTEGRATED MANUFACTURING & DISTRIBUTION PLATFORM

2 88 CDSCO

APPROVED PRODUCTS

WITH STRONG REGULATORY CAPABILITIES

3

RECURRING CONSUMABLES-LED REVENUE MODEL

4 STRONG

INSTITUTIONAL PRESENCE

ACROSS GOVERNMENT & PRIVATE HEALTHCARE

5

EXPANSION THROUGH FULLY AUTOMATED MEDICAL DEVICE PARK FACILITY

6

WELL POSITIONED TO BENEFIT FROM IMPORT SUBSTITUTION & MAKE IN INDIA

- QUALITY CERTIFICATIONS
- PAN INDIA PRESENCE
- STRATEGIC PARTNERSHIPS
- ROBUST PRODUCT PIPELINE
- SCALABLE OPERATIONS

INVESTMENT RATIONALE

Well Positioned to Capitalize on India's Growing Diagnostics & Healthcare Opportunity

Diversified Portfolio

Offering a comprehensive range of diagnostics, medical devices, analyzers and healthcare consumables across multiple healthcare segments.

88 CDSCO Approvals

Strong regulatory credentials with 88 approved products supporting market credibility and business growth.

Planned Product Expansion

The Company intends to expand its product portfolio through 200+ applications planned for submission and regulatory review over time.

Pan-India Network

Established distribution network serving customers across multiple states and healthcare markets across India.

Recurring Revenue Model

Consumables and reagents business generates repeat orders, enhancing revenue visibility and business stability.

Manufacturing Strength

Integrated manufacturing capabilities supported by quality control systems and regulatory compliance standards.

Expansion Focused

Upcoming manufacturing facility expected to strengthen capacity, operational efficiency and future scalability.

B2B Healthcare Focus

Serving hospitals, pathology laboratories, research institutions and healthcare organizations across the country.

CERTIFICATIONS, COMPLIANCE & QUALITY EXCELLENCE

Globally Recognized Standards. Quality Assured. Built for Trust.

AVIENbio®
Complete Healthcare Solution

1. ISO 13485:2016 (IAF MLA)



Quality Management System for Medical Devices

- IAF MLA Recognized
- International Medical Device Quality Standard
- Covers Manufacturing & Supply of Diagnostic Products

2. ISO 9001:2015 (AF MLA)

Quality Management System

- IAF MLA Recognized
- Standardized Quality Processes
- Continuous Improvement Framework

3. CE CERTIFICATION (UK CERT LTD)

Affirms conformity with European health, safety & environmental protection standards

- European Conformity Certification
- Health, Safety & Environmental Compliance
- Supports International Market Access

4. WHO-GMP COMPLIANCE CERTIFICATE (UK CERT LTD)

Quality Management system satisfactorily as per the norms of "Good Manufacturing Practice"

- Good Manufacturing Practice (GMP) Compliant
- Quality Management System Verified
- Covers Diagnostic Reagents, Kits & Medical Devices

5. GeM & QCI VENDOR ASSESSMENT REPORT

- Assessed by Quality Council of India (QCI)
- Government e Marketplace (GeM) Verified
- Vendor Quality & Process Assessment Completed

6. ZED GOLD CERTIFICATE

- MSME Sustainable Manufacturing Recognition
- Zero Defect Zero Effect (ZED)
- Focus on Quality, Sustainability & Operational Excellence

REGULATORY & QUALITY EXCELLENCE

REGULATORY STRENGTH

88
CDSCO
APPROVED PRODUCTS

88 CDSCO
APPROVED PRODUCTS

200+ APPLICATIONS
UNDER PROCESS

STRONG UNDERSTANDING
OF REGULATORY FRAMEWORK

PRODUCT APPROVAL EXPERTISE
ACROSS MULTIPLE DIAGNOSTIC
CATEGORIES

REGULATORY APPROVAL JOURNEY

APPLICATION → TESTING & EVALUATION → DOCUMENTATION REVIEW → APPROVAL → COMMERCIALIZATION

MEDICAL DEVICE APPROVALS INVOLVE LENGTHY REGULATORY PROCESSES, CREATING STRONG ENTRY BARRIERS FOR NEW PLAYERS.

QUALITY & COMPLIANCE

ISO 13485:2016
CERTIFIED

ISO 9001:2015
CERTIFIED

QUALITY FOCUSED
MANUFACTURING
PROCESSES

COMPLIANCE DRIVEN
PRODUCT DEVELOPMENT

FOCUS ON PRODUCT
RELIABILITY & ACCURACY

BUILDING TRUST THROUGH
REGULATORY EXCELLENCE & QUALITY STANDARDS

WAY FORWARD

1. EXPAND MANUFACTURING CAPACITY

Expand Manufacturing Capacity through the upcoming fully automated Medical Device Park facility to support higher volumes and product diversification.

2. ACCELERATE PRODUCT APPROVALS & COMMERCIALIZATION

Accelerate Product Approvals & Commercialization by converting the 200+ product applications under process into market-ready products and strengthening the product portfolio.

3. STRENGTHEN DOMESTIC PRESENCE & BUILD EXPORT MARKETS

Strengthen Domestic Presence & Build Export Markets by deepening penetration across government hospitals, private labs, diagnostic centers, and healthcare institutions while expanding into international markets through strategic partnerships and regulatory approvals.

FUTURE OUTLOOK

Building the Next Phase of Growth

288+

Products

Expanded Product Portfolio

Target to expand to 288+ approved products from 88+ currently

60%

Revenue Growth

FY27 Growth Target

Driven by Capacity Expansion, Product Launches & Wider Distribution

KEY GROWTH DRIVERS

- Expansion of product portfolio to **288+ products**
- Commercialisation of newly approved products
- Scale-up through the new automated manufacturing facility
- Strong pipeline of government & PSU tenders – Recent win of ₹47.46 Cr order to be executed within 3–4 months
- Focus on exports for geographic diversification

Building the foundation for sustained long-term growth.

MANAGEMENT COMMENTARY

Mr. Dharam Deo Choudhary
Promoter & Managing Director
Avience Biomedicals Limited

"FY26 has been a landmark year for Avience Biomedicals, marked by robust financial performance, **successful completion of our IPO**, and strong progress across our strategic growth initiatives. We are grateful to our investors for their trust and confidence, and remain committed to delivering innovative, reliable, and affordable diagnostic solutions while creating sustainable long-term value for all stakeholders.

Our strong FY26 performance reflects the successful execution of our growth strategy, with higher revenue, improved profitability, and increasing market acceptance of our products. The IPO proceeds will play a pivotal role in establishing our new **state-of-the-art manufacturing facility** at the Medical Device Park, Yamuna Expressway, significantly enhancing our production capacity and supporting future expansion.

Looking ahead, we are entering an exciting phase of growth. We **plan to file regulatory approval applications for over 200 additional products**, while accelerating the commercialization of our **88 CDSCO-approved products** across biochemistry, rapid diagnostics, hematology, microbiology, and other diagnostic segments. These initiatives, together with our enhanced manufacturing capabilities, continuous innovation, and unwavering focus on quality, position us strongly to capture the growing opportunities in both domestic and international markets.

Furthermore, we are expanding into new avenues through **exports and government tenders**. We are pleased to share that we have recently secured a **₹47.46 Cr order from a PSU**, which is approximately equivalent to our FY26 revenue and is **scheduled to be executed within 3–4 months**. This is a significant milestone and validates our product quality, capabilities, and credibility in serving large-scale public sector requirements.

With these growth drivers in place, we are confident of delivering **at least 60% revenue growth in FY27** and remain focused on building a globally competitive diagnostics company that consistently creates value for customers, partners, and shareholders."

FINANCIAL HIGHLIGHTS

AVIENbio®
Complete Healthcare Solution

Strong Growth. Improving Profitability. Consistent Performance.

REVENUE FROM OPERATIONS
(₹ Lakhs)



EBITDA
(₹ Lakhs)



PAT
(₹ Lakhs)



FINANCIAL HIGHLIGHTS

Strengthening Margins. Improving Returns. Consistent Value Creation.

EBITDA MARGIN (%)



ROE (%)



ROCE (%)



FINANCIAL HIGHLIGHTS

Strong Growth. Improving Profitability. Consistent Performance.

Consolidated Statement of Profit and Loss (₹ Lakhs) (All amounts in ₹ Lakhs, unless otherwise stated)	FY25 (Mar 31, 2025) Audited	FY26 (Mar 31, 2026) Audited
A. REVENUE		
Revenue from Operations	4,523.59	5,250.58
Other Income	67.25	28.92
Total Revenue (Total Income)	**4,590.84**	**5,279.50**
B. EXPENSES		
Cost of Materials Consumed	330.22	562.01
Purchase of Stock-in-Trade	2,446.19	2,698.36
Changes in Inventories	(70.06)	(377.30)
Employee Benefit Expense	321.06	451.71
Finance Cost	141.60	153.95
Depreciation Expense	88.18	122.16
Other Expenses	349.29	422.02
Total Expenses	**3,606.47**	**4,032.92**
C. PROFIT AND TAX		
Profit before prior period items & tax (PBT)	984.38	1,246.58
Less: Prior period items	7.50	-
Profit before tax (PBT)	**976.88**	**1,246.58**
Tax Expense	266.97	371.30
Profit After Tax (PAT)	**709.90**	**875.28**

Note: *Figures are audited as per the consolidated financial statements.*

BALANCE SHEET HIGHLIGHTS

Strengthening Financial Position Through Asset Expansion and Net Worth Growth.

(₹ Lakhs)

EQUITY & LIABILITIES Particulars (₹ Lakhs)	FY25 (Mar 31, 2025)	FY26 (Mar 31, 2026)
1. SHAREHOLDER'S FUNDS		
Share Capital	403.13	403.13
Reserves & Surplus	1,862.85	2,738.12
TOTAL EQUITY	**2,265.98**	**3,141.25**
2. NON-CURRENT LIABILITIES		
Long Term Borrowings	984.95	1,322.87
Deferred Tax Liabilities (Net)	14.68	18.64
Long Term Provisions	24.05	15.97
TOTAL NON-CURRENT LIABILITIES	**1,023.68**	**1,357.48**
3. CURRENT LIABILITIES		
Short Term Borrowings	1,230.87	1,570.61
Trade Payables		
(a) Total outstanding dues of micro enterprises and small enterprises	101.86	186.83
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	624.97	760.63
Other Current Liabilities	142.62	442.98
Short Term Provisions	258.86	334.61
TOTAL CURRENT LIABILITIES	**2,359.18**	**3,295.66**
TOTAL EQUITY & LIABILITIES	**5,648.84**	**7,794.39**

ASSETS Particulars (₹ Lakhs)	FY25 (Mar 31, 2025)	FY26 (Mar 31, 2026)
1. NON-CURRENT ASSETS		
Property, Plant & Equipment	1,295.92	1,591.64
Capital Work-in-Progress	461.91	1,285.28
Goodwill on Consolidation	14.46	14.46
Non Current Investments	2.75	2.75
Deferred Tax Assets (Net)	7.40	3.49
Long Term Loans & Advances	111.02	205.27
Other Non Current Assets	38.14	37.60
TOTAL NON CURRENT ASSETS	**1,931.60**	**3,140.49**
2. CURRENT ASSETS		
Inventories	1,307.12	1,717.53
Trade Receivables	1,721.06	2,101.72
Cash & Cash Equivalents	493.65	293.44
Short Term Loans & Advances	186.43	526.16
Other Current Assets	8.98	15.05
TOTAL CURRENT ASSETS	**3,717.24**	**4653.90**
TOTAL ASSETS	**5,648.84**	**7,794.39**

Note: Figures are for the year ended March 31 for FY25 and FY26.

REVENUE MIX – DOMESTIC vs EXPORT

Strong Domestic Presence. Expanding Global Reach.

Particulars	FY25 Share (%)	FY26 Share (%)
Domestic	81.85%	98.99%
Exports	18.15%	1.01%
Total Revenue from Operations	100.00%	100.00%

Our revenue mix continues to be predominantly driven by the **domestic market**, contributing **98.99%** in FY26, while **exports** contributed **1.01%**.

THANK YOU

AVIENbio®
Complete Healthcare Solution

MOONWALK CAPITAL
Elevating Vision. Empowering Growth.

Contact Information

Moonwalk Capital IR Team

Phone: +917014618970

E-mail: investorrelations@moonwalkcapitaladvisors.com